Clinical Trial Update: A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy [Phase 3]

View source ↗

Summary

A Phase IIIB trial evaluating the effect of switching to atazanavir on serum lipid levels in HIV-infected individuals virologically suppressed on their first pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• REYATAZ (atazanavir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: HIV Infections | Phase 3 | Status: COMPLETED